NBIX — Neurocrine Biosciences Inc. stock price and chart

Share this page

NBIX

$143.18+1.76%

as of close, Oct 2, 2026

☾ AH $143.18 +1.76%

Neurocrine Biosciences Inc.Stock · Health CareNasdaq Composite 0.03%Russell 1000 0.02%US Stock Market 0.02%Russell 3000 0.02%MSCI World 0.02%MSCI ACWI 0.02%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

40.060.080.0100.0120.0140.0160.0180.0010.0M20.0M$143.18

2026-10-02

Price$143.18

MA20$156.37

MA50$145.29

Vol9.6M

What would $1,000 invested in NBIX be worth today? →

NBIX returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $143.18
Change YTD: +0.95%
Next earnings: Oct 27, 2026
Market cap: 14.6B2016-12 3.4B2026-10 14.6B+332.9% over the window
Enterprise value: 14.7B
Shares outstanding: 101.6M2016-06 86.8M2026-06 101.6M+17.2% over the window
52W low: $122.14
52W high: $186.12
From 52W high: -23.07%
From 52W low: +17.23%
52W range: 33%
Beta: 0.39

Volume

Rel volume: 1.32×
30D volume: 1.2M
30D $ vol: 185M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1M0 insider-days of buying (no priced lot) and 3 of selling ($826K) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$826K
Insider net 3M0 insider-days of buying (no priced lot) and 9 of selling ($6.2M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$6.2M
Insider net 1Y0 insider-days of buying (no priced lot) and 22 of selling ($68.1M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$68.1M

Form 4 transactions by trade date, as filed; latest on file 2026-09-14.

Fundamentals

Sales (ttm): 3.4B2016-06 15M2026-06 3.4B+22392.7% over the window
Sales/share: $33.192016-06 $0.172026-06 $33.19+19096.2% over the window
EPS (ttm): $6.812016-12 -$1.632026-06 $6.81-518.1% over the window
FCF (ttm): 870.4M2016-06 -81.4M2026-06 870.4M-1168.6% over the window
FCF/share: $8.562016-06 -$0.942026-06 $8.56-1012.0% over the window
Book value/share: $36.342016-06 $4.392026-06 $36.34+727.3% over the window
Net margin: 20.91%2016-06 -822.0%2026-06 20.9%-102.5% over the window
ROE: 19.10%2016-06 -32.4%2026-06 19.1%-159.0% over the window
ROA: 13.16%2016-06 -28.7%2026-06 13.2%-145.9% over the window
Current ratio: 1.872016-06 14.572026-06 1.87-87.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: +34.45%2025-06-30 → 2026-06-302.5B → 3.4B (+34.4% total)+26.33%2023-06-30 → 2026-06-301.7B → 3.4B (+101.7% total)+26.74%2021-06-30 → 2026-06-301B → 3.4B (+227.0% total)+71.88%2016-06-30 → 2026-06-3015M → 3.4B (+22392.7% total)
Net income: +102.65%2025-06-30 → 2026-06-30348.3M → 705.5M (+102.6% total)+58.72%2023-06-30 → 2026-06-30176.4M → 705.5M (+299.9% total)+14.11%2021-06-30 → 2026-06-30364.7M → 705.5M (+93.4% total)n/a
FCF: +64.69%2025-06-30 → 2026-06-30528.7M → 870.4M (+64.6% total)+45.79%2023-06-30 → 2026-06-30280.8M → 870.4M (+210.0% total)+28.25%2021-06-30 → 2026-06-30250.9M → 870.4M (+246.9% total)n/a
Shares: +2.49%2025-06-30 → 2026-06-3099.2M → 101.6M (+2.5% total)+1.35%2023-06-30 → 2026-06-3097.7M → 101.6M (+4.1% total)+1.44%2021-06-30 → 2026-06-3094.6M → 101.6M (+7.4% total)+1.60%2016-06-30 → 2026-06-3086.8M → 101.6M (+17.2% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +100.94%2025-06-30 → 2026-06-30$3.39 → $6.81 (+100.8% total)+56.50%2023-06-30 → 2026-06-30$1.78 → $6.81 (+283.4% total)+12.87%2021-06-30 → 2026-06-30$3.72 → $6.81 (+83.2% total)n/a
Sales/share: +31.18%2025-06-30 → 2026-06-30$25.31 → $33.19 (+31.2% total)+24.66%2023-06-30 → 2026-06-30$17.13 → $33.19 (+93.7% total)+24.94%2021-06-30 → 2026-06-30$10.90 → $33.19 (+204.4% total)+69.18%2016-06-30 → 2026-06-30$0.17 → $33.19 (+19096.2% total)
FCF/share: +60.69%2025-06-30 → 2026-06-30$5.33 → $8.56 (+60.6% total)+43.86%2023-06-30 → 2026-06-30$2.88 → $8.56 (+197.8% total)+26.43%2021-06-30 → 2026-06-30$2.65 → $8.56 (+223.0% total)n/a
Book value/share: +33.79%2025-06-30 → 2026-06-30$27.17 → $36.34 (+33.8% total)+24.17%2023-06-30 → 2026-06-30$18.98 → $36.34 (+91.5% total)+21.87%2021-06-30 → 2026-06-30$13.52 → $36.34 (+168.9% total)+23.53%2016-06-30 → 2026-06-30$4.39 → $36.34 (+727.3% total)
Price: +4.71%2025-10-02 → 2026-10-02$136.74 → $143.18 (+4.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+8.60%2023-10-02 → 2026-10-02$111.79 → $143.18 (+28.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+7.13%2021-10-01 → 2026-10-02$101.46 → $143.18 (+41.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.95%2016-09-30 → 2026-10-02$50.64 → $143.18 (+182.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +4.71%2025-10-02 → 2026-10-02$136.74 → $143.18 (+4.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+8.60%2023-10-02 → 2026-10-02$111.79 → $143.18 (+28.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+7.13%2021-10-01 → 2026-10-02$101.46 → $143.18 (+41.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.95%2016-09-30 → 2026-10-02$50.64 → $143.18 (+182.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 21.0×2016-12 -26.742026-10 20.63-177.2% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 18.3×2016-12 -25.492026-10 18.31-171.8% over the window
Fwd P/E: 11.6×
P/S (ttm)Market cap ÷ TTM revenue.: 4.3×2016-12 224.132026-10 4.31-98.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.9×2016-12 9.562026-10 3.94-58.8% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 16.7×2016-12 -35.632026-10 16.72-146.9% over the window
EV/EBITDA (fy): 17.4×
EV/Sales (ttm): 4.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 5.98%2016-09 -2.8%2026-06 5.1%-281.0% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 101.6M ÷ 99.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -2.49%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-2.49%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($12.5B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -2.49%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-125.3M) ÷ today's market cap ($14.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -0.86%2016-09 -0.1%2026-06 -0.7%+646.2% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-125.3M + TTM dividends $0) ÷ today's market cap ($14.6B). Same caveat as the cash buyback yield.: -0.86%2016-09 -0.1%2026-06 -0.7%+646.2% over the window

Vs own 10Y history

P/E: 4th
P/OI: 2nd
P/S: 2nd
P/B: 2nd
P/FCF: 2nd

Bar = where today’s multiple sits in NBIX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-02

+1.76%

+3.45%

-9.26%

-17.84%

YTD

+0.95%

+4.71%

+41.12%

Recent filings

Sep 288-K · Directors or officers; compensation
Sep 14Insider sale · ABERNETHY MATT (Chief Financial Officer) sold 2,311 shares for $363K at $157.20 under a 10b5-1 plan
Sep 14Insider sale · Boyer David W. (Chief Corp. Affairs Officer) sold 826 shares for $130K at $157.45 under a 10b5-1 plan
Sep 9Insider sale · BENEVICH ERIC (Chief Commercial Officer) sold 2,154 shares for $333K at $154.61 under a 10b5-1 plan
Jul 31Report · Quarterly report, Q2 2026 — revenue $959.0M (+39% y/y), net income $144.4M, EPS $1.39

All filings and insider trades →

Financial statements

Open full NBIX financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-13.21%	-0.04%
NVO	Novo Nordisk A/S	-20.21%	-0.21%
SNY	Sanofi ADS	-10.23%	-1.84%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-6.76%	-0.32%
NTRA	Natera Inc.	+26.20%	+0.46%
ARGX	argenx SE American Depositary Shares	-12.90%	-1.79%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	-3.09%	+0.00%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+5.44%	+0.56%

NBIX — Neurocrine Biosciences Inc. price, chart and key statistics